Andrew Hack

Biography

Andrew joined Editas Medicine as CFO in July 2015. Previously, he served as a portfolio manager at Millennium Management, where he ran a healthcare fund focused on biotechnology, pharmaceutical and medical device companies from May 2011 to June 2015. Prior to Millennium, Andrew was an analyst at HealthCor Management from December 2008 to May 2011. Prior to HealthCor Management, Andrew was an analyst Carlyle-Blue Wave Partners and a principal of the MPM BioEquities Fund. He started his investment career covering the biotechnology sector at Banc of America Securities after co-founding of Reify Corporation, a life science tools and drug discovery company. Andrew received his B.A. in biology with special honors from the University of Chicago, where he also received his M.D. and Ph.D., was named the inaugural Frank Family Scholar, and received awards from the American Heart Association and the American Society for Cell Biology. In addition to his role at Editas, Andrew is a member of the board of directors of Mersana Therapeutics.

Research Interest

biotechnology, pharmaceutical and medical device and Cell Biology